Telix Reshapes Capital Structure With US$600m Convertible Issue and Bond Buyback

An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.

Telix Pharmaceuticals has settled a US$600 million issuance of 1.50% convertible notes due 2031 through its U.S. investment subsidiary, with the bonds expected to list on the Singapore Exchange. The transaction, led by J.P. Morgan as sole bookrunner, positions the company with longer-dated, lower-cost capital while broadening its access to international debt investors.

In parallel, Telix has substantially completed the repurchase of approximately A$637 million of its existing A$650 million 2.375% convertible bonds due 2029, representing about 98% of that issue. With less than 15% of the older bonds outstanding, Telix plans to redeem and cancel the remainder, simplifying its capital structure and extending its debt maturity profile in support of future growth plans.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals aimed at addressing significant unmet medical needs in oncology and rare diseases. Headquartered in Melbourne, the company operates across major markets including the U.S., U.K., Brazil, Canada, Europe and Japan, and is dual listed on the ASX and Nasdaq.

Average Trading Volume: 3,270,011

Technical Sentiment Signal: Hold

Current Market Cap: A$5.01B

For an in-depth examination of TLX stock, go to TipRanks’ Overview page.